Dimerix Valuation
Is DXB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DXB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DXB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DXB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DXB?
Key metric: As DXB barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is DXB's PB Ratio? | |
|---|---|
| PB Ratio | 10x |
| Book | AU$18.19m |
| Market Cap | AU$181.07m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 272.6x |
| Enterprise Value/EBITDA | -9.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does DXB's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4x | ||
IMU Imugene | 2.5x | 53.4% | AU$275.2m |
IMM Immutep | 2.3x | 38.6% | AU$414.6m |
ARX Aroa Biosurgery | 2.6x | 56.3% | AU$224.2m |
BTG Beroni Group | 8.7x | n/a | AU$75.9m |
DXB Dimerix | 10x | n/a | AU$181.1m |
Price-To-Book vs Peers: DXB is expensive based on its Price-To-Book Ratio (10x) compared to the peer average (2.4x).
Price to Book Ratio vs Industry
How does DXB's PB Ratio compare vs other companies in the AU Biotechs Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
BNO Bionomics | 0.3x | -36.0% | US$9.52m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: DXB is expensive based on its Price-To-Book Ratio (10x) compared to the Australian Biotechs industry average (3.1x).
Price to Book Ratio vs Fair Ratio
What is DXB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 10x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate DXB's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Little Green Pharma
AU$39.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.1%
AVITA Medical
US$342.3m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.98
7D
0.5%
1Y
19.9%
Neuren Pharmaceuticals
AU$1.6b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$12.36
7D
-26.0%
1Y
-17.0%